LT3538554T - Antigeną surišantys baltymai, antagonizuojantys leptino receptorius - Google Patents

Antigeną surišantys baltymai, antagonizuojantys leptino receptorius

Info

Publication number
LT3538554T
LT3538554T LTEPPCT/US2017/060690T LTUS2017060690T LT3538554T LT 3538554 T LT3538554 T LT 3538554T LT US2017060690 T LTUS2017060690 T LT US2017060690T LT 3538554 T LT3538554 T LT 3538554T
Authority
LT
Lithuania
Prior art keywords
antigen
binding proteins
leptin receptor
antagonize
antagonize leptin
Prior art date
Application number
LTEPPCT/US2017/060690T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jesper Gromada
Panayiotis Stevis
Judith Altarejos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LT3538554T publication Critical patent/LT3538554T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEPPCT/US2017/060690T 2016-11-08 2017-11-08 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius LT3538554T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419062P 2016-11-08 2016-11-08
PCT/US2017/060690 WO2018089532A1 (en) 2016-11-08 2017-11-08 Antigen-binding proteins that antagonize leptin receptor

Publications (1)

Publication Number Publication Date
LT3538554T true LT3538554T (lt) 2025-10-10

Family

ID=60409473

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/060690T LT3538554T (lt) 2016-11-08 2017-11-08 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius

Country Status (29)

Country Link
US (3) US10550192B2 (cg-RX-API-DMAC7.html)
EP (2) EP4613772B1 (cg-RX-API-DMAC7.html)
JP (4) JP7042816B2 (cg-RX-API-DMAC7.html)
KR (1) KR102563568B1 (cg-RX-API-DMAC7.html)
CN (1) CN110167965A (cg-RX-API-DMAC7.html)
AU (2) AU2017359439B2 (cg-RX-API-DMAC7.html)
CA (1) CA3043365A1 (cg-RX-API-DMAC7.html)
CL (3) CL2019001263A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019004672A2 (cg-RX-API-DMAC7.html)
DK (1) DK3538554T3 (cg-RX-API-DMAC7.html)
EA (1) EA201991075A1 (cg-RX-API-DMAC7.html)
ES (1) ES3040144T3 (cg-RX-API-DMAC7.html)
FI (1) FI3538554T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251165T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073276T2 (cg-RX-API-DMAC7.html)
IL (2) IL266426B (cg-RX-API-DMAC7.html)
LT (1) LT3538554T (cg-RX-API-DMAC7.html)
MA (1) MA45801B1 (cg-RX-API-DMAC7.html)
MX (2) MX2019005397A (cg-RX-API-DMAC7.html)
MY (2) MY203682A (cg-RX-API-DMAC7.html)
PH (1) PH12019500988A1 (cg-RX-API-DMAC7.html)
PL (1) PL3538554T3 (cg-RX-API-DMAC7.html)
PT (1) PT3538554T (cg-RX-API-DMAC7.html)
RS (1) RS67214B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201913470SA (cg-RX-API-DMAC7.html)
SI (1) SI3538554T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500327T1 (cg-RX-API-DMAC7.html)
UA (1) UA127678C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018089532A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
MA45801B1 (fr) 2016-11-08 2021-11-30 Regeneron Pharma Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
SMT202500283T1 (it) 2018-04-06 2025-09-12 Regeneron Pharma Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
WO2020016160A1 (en) * 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
CN113195532B (zh) * 2018-12-18 2025-04-11 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20230038524A (ko) * 2020-07-17 2023-03-20 스미토모 세이카 가부시키가이샤 흡수체
BR112023004716A2 (pt) * 2020-09-15 2023-05-09 Regeneron Pharma Uso de agonistas de lepr para dor
CN118436632B (zh) * 2024-07-05 2024-08-30 四川大学华西第二医院 Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU721129B2 (en) 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
AU731685C (en) 1996-01-23 2002-08-22 Indevus Pharmaceuticals, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
ES2289235T3 (es) * 2003-08-21 2008-02-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Nuevo antagonista de leptina.
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
FI3366705T3 (fi) 2012-09-12 2023-07-28 Genzyme Corp Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
EP3108255B1 (en) 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
MA45801B1 (fr) 2016-11-08 2021-11-30 Regeneron Pharma Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine

Also Published As

Publication number Publication date
MY203682A (en) 2024-07-12
KR20190075133A (ko) 2019-06-28
US20180127508A1 (en) 2018-05-10
JP7875904B2 (ja) 2026-06-18
EP4613772A3 (en) 2025-12-24
CL2020000549A1 (es) 2020-08-28
CL2019001263A1 (es) 2019-09-27
PH12019500988A1 (en) 2019-08-19
MA45801B1 (fr) 2021-11-30
EP3538554A1 (en) 2019-09-18
UA127678C2 (uk) 2023-11-29
JP2020504078A (ja) 2020-02-06
JP2023093753A (ja) 2023-07-04
CN110167965A (zh) 2019-08-23
FI3538554T3 (fi) 2025-09-24
CL2020001023A1 (es) 2020-10-09
IL266426A (en) 2019-06-30
CA3043365A1 (en) 2018-05-17
WO2018089532A1 (en) 2018-05-17
JP2022031969A (ja) 2022-02-22
RS67214B1 (sr) 2025-10-31
JP7042816B2 (ja) 2022-03-28
IL272358A (en) 2020-03-31
AU2017359439A1 (en) 2019-05-23
US20230235068A1 (en) 2023-07-27
AU2017359439B2 (en) 2024-11-28
MY191256A (en) 2022-06-10
KR102563568B1 (ko) 2023-08-04
US20200123264A1 (en) 2020-04-23
US10550192B2 (en) 2020-02-04
HUE073276T2 (hu) 2026-01-28
EA201991075A1 (ru) 2019-10-31
MA45801A1 (fr) 2020-07-29
EP3538554B1 (en) 2025-08-13
PT3538554T (pt) 2025-09-01
MX2023011233A (es) 2023-10-03
MX2019005397A (es) 2019-10-09
US11535675B2 (en) 2022-12-27
AU2025201454A1 (en) 2025-04-10
ES3040144T3 (en) 2025-10-28
IL272358B (en) 2022-02-01
PL3538554T3 (pl) 2025-10-27
JP2024109952A (ja) 2024-08-14
DK3538554T3 (da) 2025-09-08
JP7611292B2 (ja) 2025-01-09
IL266426B (en) 2020-11-30
SMT202500327T1 (it) 2025-11-10
SG10201913470SA (en) 2020-03-30
EP4613772A2 (en) 2025-09-10
HRP20251165T1 (hr) 2025-11-21
EP4613772B1 (en) 2026-07-22
CO2019004672A2 (es) 2019-07-31
SI3538554T1 (sl) 2025-10-30

Similar Documents

Publication Publication Date Title
SG10201913432RA (en) Antigen-binding proteins that activate the leptin receptor
HUS2500024I1 (hu) ANTI-PD-1 ellenanyagok
ZA201900353B (en) Anti-pd-l1 antibodies
SG10201913470SA (en) Antigen-binding proteins that antagonize leptin receptor
ZA201803874B (en) Humanized anti-cd73 antibodies
IL262295A (en) Antibodies against pd-l1
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
PL3512547T3 (pl) Przeciwciała anty-pd-1
IL257062A (en) New anti-pd-1 antibodies
SG11202013138RA (en) Anti-steap1 antigen-binding protein
IL253909A0 (en) Humanized *anti–muc1 antibodies
EP3274366B8 (en) Chimeric antigen receptor
SG11201705552QA (en) Anti-pd-l1 antibodies
ZA201807167B (en) Humanized anti-il-1r3 antibodies
IL256579A (en) Human antibodies
PT3101131T (pt) Anticorpo antitranstirretina humanizado
EP3119812A4 (en) Bi-specific antigen-binding polypeptides
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
HK40006638A (en) Antigen-binding proteins that antagonize leptin receptor
GB201804154D0 (en) Optimisation methods
GB201612035D0 (en) Optimisation